Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: A post-hoc analysis of the longitudinal Whitehall II cohort study

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 1, 2013, Pages 43-51

  Færch, Kristine ^a   Witte, Daniel R ^a,b   Tabák, Adam G ^c,d   Perreault, Leigh ^e   Herder, Christian ^f   Brunner, Eric J ^c   Kivimäki, Mika ^c   Vistisen, Dorte ^a  

^a STENO DIABETES CENTER   (Denmark)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY OF COLORADO   (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; BLOOD; CARDIOVASCULAR DISEASES; CLASSIFICATION; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; FOLLOW UP; METABOLISM; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84882567239     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70008-1     Document Type: Article

References (31)

1. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009, 373:2215-2221.
2. Færch K, Vaag A, Holst JJ, Hansen T, Jørgensen T, Borch-Johnsen K Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting gycemia and impaired glucose tolerance-the Inter99 study. Diabetes Care 2009, 32:439-444.
3. Perreault L, Bergman BC, Playdon MC, Dalla Man C, Cobelli C, Eckel RH Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?. Am J Physiol Endocrinol Metab 2008, 295:E428-E435.
4. Weyer C, Bogardus C, Pratley RE Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999, 48:2197-2203.
5. Engberg S, Vistisen D, Lau C, et al. Progression to impaired glucose regulation and diabetes in the population-based Inter99 study. Diabetes Care 2009, 32:606-611.
6. Marmot M, Brunner E Cohort profile: the Whitehall II study. Int J Epidemiol 2005, 34:251-256.
7. Alberti KGMM, Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Diabetic Med 1998, 15:539-553.
8. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993, 39:578-582.
9. Tabák AG, Carstensen M, Witte DR, et al. Adiponectin trajectories before type 2 diabetes diagnosis. Diabetes Care 2012, 35:2540-2547.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
11. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI0,120): comparison with other measures. Diabetes Res Clin Pract 2000, 47:177-184.
12. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. Circulation 2008, 117:743-753.
13. Benjamini Y, Hochberg Y Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat B 1995, 57:289-300.
14. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334. International Expert Committee.
15. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes 2003, 52:1475-1484.
16. Van Haeften TW, Pimenta W, Mitrakou A, et al. Disturbances in beta-cell function in impaired fasting glycemia. Diabetes 2002, 51(suppl):S265-S270.
17. Færch K, Borch-Johnsen K, Holst JJ, Vaag A Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?. Diabetologia 2009, 52:1714-1723.
18. Engberg S, Glümer C, Witte D, Jørgensen T, Borch-Johnsen K Differential relationship between physical activity and progression to diabetes by glucose tolerance status: the Inter99 Study. Diabetologia 2010, 53:70-78.
19. Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011, 171:1352-1360.
20. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
21. Jensen AC, Barker A, Kumari M, et al. Associations of common genetic variants with age-related changes in fasting and postload glucose. Diabetes 2011, 60:1617-1623.
22. Burns SF, Bacha F, Lee SJ, Tfayli H, Gungor N, Arslanian SA Declining beta-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. Diabetes Care 2011, 34:2033-2040.
23. Bock G, Man CD, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006, 55:3536-3549.
24. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999, 42:647-654. DECODE-study group on behalf of the European Diabetes Epidemiology Group.
25. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore longitudinal study on aging. Diabetes 2004, 53:2095-2100.
26. Bongaerts BWC, Rathmann W, Kowall B, et al. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy. Diabetes Care 2012, 35:1891-1893.
27. Sattar N, McConnachie A, Ford I, et al. Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2007, 56:984-991.
28. DeFronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
29. Nyamdorj R, Pitkaniemi J, Tuomilehto J, et al. Ethnic comparison of the association of undiagnosed diabetes with obesity. Int J Obes (Lond) 2010, 34:332-339.
30. Qiao Q, Nakagami T, Tuomilehto J, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000, 43:1470-1475.
31. Færch K, Borch-Johnsen K, Vaag A, Jørgensen T, Witte D Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia 2010, 53:858-865.